… Read More
Square shares are up 146% in 2020 so far, and analysts at Oppenheimer think the stock can still go higher.
On Thursday, Oppenheimer upgraded Square (SQ) to outperform, with a price target of $185. (The all-time high was $166 on Sept. 1; shares were trading at around $152 on Thursday afternoon.) The upgrade is based on the growth of Square’s Cash App, and on the company’s opportunity to help merchants transition to e-commerce.
But really, the note is a post-pandemic vote of confidence.
As Oppenheimer writes, the COVID-19 pandemic has initiated a “massive shift in digital commerce, requiring merchants to rapidly adopt omni-channel solutions.” Of course, it was already obvious before the pandemic that the retail landscape was barreling toward e-commerce, but the pandemic has sent the trend into hyperdrive. Walmart, Target, and Best Buy reported enormous surges (100%+) in digital sales in Q2; online-only retailers Etsy and Wayfair blew
… Read More
HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /PRNewswire/ – ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI; ) (“ESSA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd at 11:40am Eastern
Dr. David. R. Parkinson, Chief Executive Officer, will present a corporate overview of the Company’s business. Dr. Parkinson along with ESSA’s Chief Operating Officer, Peter Virsik, and Chief Financial Officer, David S. Wood will be available for one-on-one meetings.
The presentations will be webcast live and can be accessed through the Investor Relations page at www.essapharma.com. A replay of the presentations will be available on the Company’s website for 90 days.
Tuesday September 22, 2020
Presentation Date: Tuesday September 22, 2020
Presentation Time: 8:40am Pacific / 11:40am Eastern